Section of Vascular Surgery, Department of Excellence of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Section of Vascular Surgery, Department of Excellence of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
J Vasc Surg. 2023 Aug;78(2):387-393. doi: 10.1016/j.jvs.2023.04.040. Epub 2023 May 8.
This single-center retrospective cohort study aimed to analyze the early and long-term results of endovascular treatment for true visceral artery aneurysms (VAAs). Moreover, a comparison with the results of our previously published historical series of open surgical procedures was performed.
From January 2008 to December 2021, 78 consecutive patients were treated at our institution for true VAAs. All demographic data, procedural details, perioperative outcomes, and follow-up data were collected prospectively from a dedicated database. A retrospective analysis identified 72 patients who underwent endovascular surgery. Early results were analyzed in terms of technical success, conversion to open surgery, mortality, and local and systemic morbidities. Follow-up results were analyzed in terms of survival, need for open or endovascular reintervention, and freedom from complications at the level of the treated visceral artery. These results were then compared with those of our historical open surgical group (1982-2007), which included 54 interventions.
In four cases, the planned endovascular procedure could not be completed, and the overall technical success rate was 94.5%. No deaths occurred during the hospital stay or within 30 days after surgery. Overall, the 30-day perioperative complication rate was 5.8%, with an early reintervention rate of 2.9%. The median follow-up time was 29 months (range, 1-132 months). The estimated 7-year survival rate was 88% (standard error [SE]. 0.05). The estimated 7-year aneurysm-related complication-free rate was 85.5% (SE, 0.06), with reintervention-free and aneurysm-related complication-free survival rates of 93.3% (SE, 0.04) and 75.6% (SE, 0.07), respectively. At the 7-year follow-up, the survival rate was similar between the endovascular and open groups. There was a trend toward a higher aneurysm-related complication rate in the endovascular group than in the open group (14.5% vs 6.4%; P = .07). However, no significant differences in reintervention-free and overall estimated aneurysm-related complication-free survival rates were found between the two groups.
Endovascular repair is safe and effective in patients with VAAs, with low perioperative complication rates. The long-term outcomes were satisfactory and comparable with those of the historical series of open surgical repairs. Even if there is a trend toward a higher risk of late aneurysm-related complications among endovascular patients, it does not imply an increased need for late reinterventions.
本单中心回顾性队列研究旨在分析腔内治疗真性内脏动脉动脉瘤(VAAs)的早期和长期结果。此外,还与我们之前发表的开放手术系列历史结果进行了比较。
自 2008 年 1 月至 2021 年 12 月,我院对 78 例真性 VAAs 患者进行了治疗。所有人口统计学数据、手术细节、围手术期结果和随访数据均从专用数据库中前瞻性收集。回顾性分析确定了 72 例行血管内手术的患者。早期结果分析包括技术成功率、转为开放手术、死亡率、局部和全身并发症。随访结果分析包括生存、开放或血管内再干预的需要,以及治疗内脏动脉水平无并发症的情况。然后将这些结果与我们的历史开放手术组(1982-2007 年)进行比较,该组包括 54 项干预措施。
在 4 例中,计划的腔内手术无法完成,总体技术成功率为 94.5%。住院期间或术后 30 天内无死亡。总的来说,30 天围手术期并发症发生率为 5.8%,早期再干预率为 2.9%。中位随访时间为 29 个月(范围 1-132 个月)。估计的 7 年生存率为 88%(标准误差 [SE],0.05)。估计的 7 年免于动脉瘤相关并发症率为 85.5%(SE,0.06),无再干预和免于动脉瘤相关并发症的生存率分别为 93.3%(SE,0.04)和 75.6%(SE,0.07)。在 7 年随访时,血管内组和开放组的生存率相似。血管内组的动脉瘤相关并发症发生率高于开放组,呈上升趋势(14.5%比 6.4%;P =.07)。然而,两组之间无干预和总体估计免于动脉瘤相关并发症的生存率无显著差异。
腔内修复治疗 VAAs 安全有效,围手术期并发症发生率低。长期结果令人满意,与开放手术系列历史结果相当。即使血管内患者的晚期动脉瘤相关并发症风险有上升趋势,但这并不意味着晚期需要更多的再干预。